

CONFERENCE

The 7th International Drug Discovery Science and Technology. Section 8 Outsourcing, Partnership, and Licensing across the World

TITLE

Any more work for a US-based CRO?

AUTHORS

Zamas Lam

ABSTRACT

There has been an explosion of outsourcing to Asia for the past 5 – 10 years. Most pharma and some biotechs are already “on-the-ground” in China and India. Correspondingly, the number of Asian CROs (home growth, transplant, JV) is also on the rise. With the global economy this trend to outsource to Asia should continue in a fast pace. This begs the following questions: “Should all western-based CROs set-up an operation in Asia?” “Are there any more work for US-based CROs?” “What are the advantages of having just a US/EU operation or an Asian operation or both?” This presentation centers on the learnings gathered from the past 5 years by a 250 plus-people CRO that have both US and Asia operations. The learnings include: transferring the technical and operational know-how, ensuring the quality, and keeping both organizations viable and relevant in today’s global economy.